StockData
Kura Oncology, Inc. logo

Kura Oncology, Inc. (KURA) stock

KURANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 1/30
$7.34−0.15 (-2.00%)

Close on Nov 18, 2026Market cap $652.97MP/E –Yield –

Kura Oncology r&d expenses

Research and development expenses are spending on new products and technology.

Kura Oncology's R&D Expenses for the twelve months ending Sep 30, 2026 was $258.44M, up 8.2% year over year. For fiscal 2025 it was $251.07M, up 47.7% from the year before. The highest annual figure on record is $251.07M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$251.07M+47.7%
FY2024Dec 31, 2024$169.97M+47.5%
FY2023Dec 31, 2023$115.24M+24.2%
FY2022Dec 31, 2022$92.81M+9.6%
FY2021Dec 31, 2021$84.72M+40.3%
FY2020Dec 31, 2020$60.40M+26.3%
FY2019Dec 31, 2019$47.83M+2.2%
FY2018Dec 31, 2018$46.79M+77.0%
FY2017Dec 31, 2017$26.43M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$66.88M-1.5%
Q2 FY2026Jun 30, 2026$61.89M-1.4%
Q1 FY2026Mar 31, 2026$65.26M+16.6%
Q4 FY2025Dec 31, 2025$64.41M+23.2%
Q3 FY2025Sep 30, 2025$67.91M+62.8%
Q2 FY2025Jun 30, 2025$62.79M+58.0%
Q1 FY2025Mar 31, 2025$55.97M+54.3%
Q4 FY2024Dec 31, 2024$52.27M+60.7%
Q3 FY2024Sep 30, 2024$41.71M+42.2%
Q2 FY2024Jun 30, 2024$39.73M+41.0%
Q1 FY2024Mar 31, 2024$36.27M+44.0%
Q4 FY2023Dec 31, 2023$32.53M+43.5%
Q3 FY2023Sep 30, 2023$29.33M+17.4%
Q2 FY2023Jun 30, 2023$28.18M+16.2%
Q1 FY2023Mar 31, 2023$25.19M+20.5%
Q4 FY2022Dec 31, 2022$22.67M+8.2%
Q3 FY2022Sep 30, 2022$24.97M+11.7%
Q2 FY2022Jun 30, 2022$24.26M+15.1%
Q1 FY2022Mar 31, 2022$20.91M+2.9%
Q4 FY2021Dec 31, 2021$20.96M+19.6%
Q3 FY2021Sep 30, 2021$22.37M+34.7%
Q2 FY2021Jun 30, 2021$21.07M+53.9%
Q1 FY2021Mar 31, 2021$20.32M+61.6%
Q4 FY2020Dec 31, 2020$17.52M+30.2%
Q3 FY2020Sep 30, 2020$16.60M+32.4%
Q2 FY2020Jun 30, 2020$13.70M+19.7%
Q1 FY2020Mar 31, 2020$12.58M+21.1%
Q4 FY2019Dec 31, 2019$13.46M–
Q3 FY2019Sep 30, 2019$12.54M–
Q2 FY2019Jun 30, 2019$11.44M–
Q1 FY2019Mar 31, 2019$10.38M–

More Kura Oncology figures

See a number that looks wrong?